FI102183B1 - Menetelmä uusien trombiini-inhibiittoreiden valmistamiseksi - Google Patents

Menetelmä uusien trombiini-inhibiittoreiden valmistamiseksi

Info

Publication number
FI102183B1
FI102183B1 FI920672A FI920672A FI102183B1 FI 102183 B1 FI102183 B1 FI 102183B1 FI 920672 A FI920672 A FI 920672A FI 920672 A FI920672 A FI 920672A FI 102183 B1 FI102183 B1 FI 102183B1
Authority
FI
Finland
Prior art keywords
molecules
thrombin
preparation
thrombin inhibitors
relates
Prior art date
Application number
FI920672A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI102183B (fi
FI920672A0 (fi
Inventor
John M Maraganore
Ii John W Fenton
Toni Kline
Original Assignee
Biogen Inc
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27015128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI102183(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc, Health Research Inc filed Critical Biogen Inc
Publication of FI920672A0 publication Critical patent/FI920672A0/fi
Application granted granted Critical
Publication of FI102183B publication Critical patent/FI102183B/fi
Publication of FI102183B1 publication Critical patent/FI102183B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/92—Method or apparatus for preparing or treating prosthetic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polishing Bodies And Polishing Tools (AREA)
  • Prostheses (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Fats And Perfumes (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI920672A 1989-08-18 1992-02-17 Menetelmä uusien trombiini-inhibiittoreiden valmistamiseksi FI102183B1 (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US39548289A 1989-08-18 1989-08-18
US39548289 1989-08-18
US07549388 US5196404B1 (en) 1989-08-18 1990-07-06 Inhibitors of thrombin
US54938890 1990-07-06
PCT/US1990/004642 WO1991002750A1 (en) 1989-08-18 1990-08-17 Novel inhibitors of thrombin
US9004642 1990-08-17

Publications (3)

Publication Number Publication Date
FI920672A0 FI920672A0 (fi) 1992-02-17
FI102183B FI102183B (fi) 1998-10-30
FI102183B1 true FI102183B1 (fi) 1998-10-30

Family

ID=27015128

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920672A FI102183B1 (fi) 1989-08-18 1992-02-17 Menetelmä uusien trombiini-inhibiittoreiden valmistamiseksi

Country Status (18)

Country Link
US (3) US5196404B1 (no)
EP (1) EP0489070B1 (no)
JP (1) JPH0768141B2 (no)
KR (1) KR100199534B1 (no)
AT (1) ATE137246T1 (no)
AU (1) AU652125B2 (no)
CA (1) CA2065150C (no)
DE (2) DE122004000042I2 (no)
DK (1) DK0489070T3 (no)
ES (1) ES2086411T3 (no)
FI (1) FI102183B1 (no)
HK (1) HK1001562A1 (no)
HU (2) HUT60285A (no)
LU (1) LU91119I2 (no)
NL (1) NL300162I1 (no)
NO (2) NO310294B1 (no)
SG (1) SG79180A1 (no)
WO (1) WO1991002750A1 (no)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291662B1 (en) 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
US6132990A (en) * 1984-12-06 2000-10-17 Amgen Boulder Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
US5196404B1 (en) * 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
US5240913A (en) * 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
DE4005591A1 (de) * 1990-02-22 1991-09-05 Behringwerke Ag Die blutgerinnung inhibierende peptide, verfahren zu ihrer herstellung und ihre verwendung
US6060451A (en) * 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
KR100212162B1 (ko) 1990-06-15 1999-08-02 루시에 라포인테-쇼우, 카르타 커티 케이 히루딘의 아미노산 시퀸스를 기재로 한 트롬빈 억제제
US5242810A (en) * 1990-12-07 1993-09-07 Biogen, Inc. Bifunctional inhibitors of thrombin and platelet activation
KR930703024A (ko) * 1991-02-08 1993-11-29 리챠드 티. 딘 영상용 테크네튬-99m표지폴리펩티드
US5736122A (en) * 1991-02-08 1998-04-07 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5645815A (en) 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
AU659432B2 (en) * 1991-03-08 1995-05-18 Novartis Ag A method for the inhibition or prevention of tumor cell metastasis with hirudin
US5500013A (en) * 1991-10-04 1996-03-19 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
GB9209032D0 (en) * 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives
US5508020A (en) 1992-06-05 1996-04-16 Diatech, Inc. Technetium-99M labeled peptides for imaging
EP1004322B1 (en) * 1992-05-21 2006-06-14 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
AU4405293A (en) * 1992-06-05 1994-01-04 Barbara M. Alving Test for quantitative thrombin time
US5476771A (en) * 1993-02-22 1995-12-19 The United States Of America As Represented By The Secretary Of The Army Test for quantitative thrombin time
US5756291A (en) * 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US6869925B1 (en) * 1992-09-09 2005-03-22 Amgen Inc. Inhibition of retrovirus infection
FR2695562B1 (fr) * 1992-09-11 1994-10-14 Synthelabo Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un médicament à activité thrombolytique.
JPH08502261A (ja) * 1992-10-02 1996-03-12 ダイアテク，インコーポレイテッド 多重多価抗血栓症剤
DE4303646A1 (de) * 1993-02-09 1994-08-11 Basf Ag Die Verwendung von Thrombininhibitoren zur Bekämpfung neurodegenerativer Erkrankungen
US5656600A (en) * 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
IT1265023B1 (it) * 1993-04-16 1996-10-28 Dev Biotechnological Processes Inibitori della trombina, loro preparazione ed uso per applicazioni terapeutiche, profilattiche e diagnostiche
ATE246203T1 (de) * 1993-06-11 2003-08-15 Merrell Pharma Inc Trifunktionelle antithrombin-und antiplättchenpeptide
ATE198603T1 (de) * 1993-10-25 2001-01-15 Ca Nat Research Council Bivalente thrombininhibitore
DE4337599A1 (de) * 1993-11-01 1995-05-04 Diagnostikforschung Inst Metallbindende cysteinfreie Peptide für Diagnose und Therapie, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
AU1047495A (en) * 1993-11-04 1995-05-23 Brigham And Women's Hospital Plasmin-independent fibrinolysis
US6156540A (en) * 1993-12-22 2000-12-05 Human Genome Sciences, Inc. Thrombin inhibitor
JPH09504554A (ja) * 1993-12-27 1997-05-06 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント，インコーポレーテッド 血栓形成を阻止する方法及び組成物
US6017880A (en) * 1994-03-09 2000-01-25 Amgen Inc. Inhibition of retrovirus infection
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US5830448A (en) * 1994-06-16 1998-11-03 Genentech, Inc. Compositions and methods for the treatment of tumors
US5637599A (en) * 1994-06-17 1997-06-10 Corvas International, Inc. Arginine mimic derivatives as enzyme inhibitors
US5606512A (en) * 1994-07-27 1997-02-25 The Dow Chemical Company Determining the biodegradability of iminodiacetic acid derivatives
GB9426038D0 (en) 1994-12-22 1995-02-22 Iaf Biochem Int Low molecular weight bicyclic thrombin inhibitors
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US6057314A (en) * 1995-12-21 2000-05-02 Biochem Pharma Inc. Low molecular weight bicyclic thrombin inhibitors
GB9613718D0 (en) * 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
GB9613719D0 (en) * 1996-06-29 1996-08-28 Thrombosis Res Inst Serine protease inhibitors
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5985833A (en) * 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
US6010911A (en) * 1997-04-30 2000-01-04 Medtronic, Inc. Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique
US6011047A (en) * 1997-11-26 2000-01-04 Corvas International Inc. Substituted 3-amino-2-hydroxyphenylacetamide derivatives as enzyme inhibitors
US6204384B1 (en) 1997-11-26 2001-03-20 Corvas International, Inc. Substituted 3-amino-2-hydroxyphenylacetamide derivatives as enzyme inhibitors (II)
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
KR100720907B1 (ko) 1999-08-13 2007-05-25 바이오겐 아이덱 엠에이 인코포레이티드 세포 유착 억제제
CA2340461A1 (en) * 2000-03-30 2001-09-30 University Of Manitoba Hirulog-like peptide and gene therapy
DE60136926D1 (de) 2000-05-02 2009-01-22 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
ES2275737T3 (es) 2000-09-29 2007-06-16 Cordis Corporation Dispositivos medicos revestidos.
DE10149678A1 (de) 2001-10-09 2009-03-12 Novel Science International Gmbh Organische Verbindungen mit biologischer Wirkung als Thrombinhemmer und ihre Verwendung
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
DE60232184D1 (de) * 2001-12-28 2009-06-10 Prysmian Spa Wasserbeständiges telekommunikations kabel
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
DE10301255A1 (de) 2003-01-15 2004-07-29 Cpi Creative Pharma International Gmbh Organische Verbindungen mit biologischer Wirkung als Thrombinhemmer und ihre Verwendung
WO2004076484A1 (en) * 2003-02-27 2004-09-10 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants
US8791171B2 (en) 2003-05-01 2014-07-29 Abbott Cardiovascular Systems Inc. Biodegradable coatings for implantable medical devices
ATE532058T1 (de) * 2004-05-17 2011-11-15 Medtronic Inc Point-of-care-heparinbestimmungssystem
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
US7244443B2 (en) 2004-08-31 2007-07-17 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrophilic monomers
USRE46830E1 (en) * 2004-10-19 2018-05-08 Polypeptide Laboratories Holding (Ppl) Ab Method for solid phase peptide synthesis
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
JP2008543884A (ja) * 2005-09-14 2008-12-04 ノベタイド，リミティド ビバリルジンの生成方法
CN101033249B (zh) * 2006-03-10 2011-05-11 周逸明 固相多肽合成比筏芦定的制备方法
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
CN102558305B (zh) * 2007-02-08 2014-10-22 深圳信立泰药业股份有限公司 凝血酶直接抑制剂多肽水合盐及合成方法
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor
US20090062511A1 (en) * 2007-09-05 2009-03-05 Raghavendracharyulu Venkata Palle Process for the preparation of bivalirudin and its pharmaceutical compositions
US7582727B1 (en) 2008-07-27 2009-09-01 The Medicinces Company Pharmaceutical formulations of bivalirudin and processes of making the same
US7598343B1 (en) 2008-07-27 2009-10-06 The Medicines Company Pharmaceutical formulations of bivalirudin and processes of making the same
JP5788321B2 (ja) 2008-09-03 2015-09-30 サイノファーム タイワン リミテッド ビバリルジンの製造方法
SG171859A1 (en) * 2008-12-29 2011-07-28 Lonza Braine Sa Process for the production of bivalirudin
US20110160431A1 (en) 2009-04-06 2011-06-30 Novetide, Ltd. Production of peptides containing poly-gly sequences using fmoc chemistry
GB0907698D0 (en) * 2009-05-05 2009-06-10 Univ Singapore Method of modifying serine protease inhibitors
CN101555274B (zh) * 2009-05-15 2013-08-21 海南双成药业股份有限公司 一种多肽固相合成比法卢定粗品的制备方法
US7803762B1 (en) * 2009-08-20 2010-09-28 The Medicines Company Ready-to-use bivalirudin compositions
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
SI2498731T1 (sl) 2009-11-11 2020-05-29 Chiesi Farmaceutici S.P.A. Postopki zdravljenja ali preprečevanja tromboze stenta
US7985733B1 (en) 2010-01-06 2011-07-26 The Medicines Company Buffer-based method for preparing bivalirudin drug product
EP2471945A1 (de) * 2010-12-30 2012-07-04 Siemens Healthcare Diagnostics Products GmbH Verfahren zur Bestimmung von Inhibitoren der Gerinnung
WO2013042129A1 (en) 2011-09-23 2013-03-28 Natco Pharma Limited Improved process for preparation of bivalirudin
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
ES2929218T3 (es) 2015-01-12 2022-11-28 Enteris Biopharma Inc Formas farmacéuticas orales sólidas
CN113201049B (zh) * 2015-08-05 2022-10-04 陕西麦科奥特科技有限公司 有抗凝血和抗血小板活性的多靶点化合物及制法和用途
CA3060345A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
WO2020236150A1 (en) * 2019-05-20 2020-11-26 MAIA Pharmaceuticals, Inc. Ready-to-use bivalirudin compositions
US11903993B2 (en) 2019-05-20 2024-02-20 MAIA Pharmaceuticals, Inc. Ready-to-use bivalirudin compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55500091A (no) * 1978-02-17 1980-02-14
CA1341032C (en) * 1987-01-23 2000-06-20 John L. Krstenansky Anticoagulant peptides
CA1328540C (en) * 1987-05-21 1994-04-12 John L. Krstenansky Cyclic anticoagulant peptides
ZA883443B (en) * 1987-05-21 1988-11-16 Merrell Dow Pharmaceuticals Inc. Cyclic anticoagulant peptides
EP0333356A3 (en) * 1988-03-04 1990-12-19 Biogen, Inc. Hirudin peptides
NZ228995A (en) * 1988-05-10 1992-03-26 Merrell Dow Pharma Hirudin peptide derivatives and pharmaceutical compositions
US5167960A (en) * 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
US5196404B1 (en) * 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
KR100212162B1 (ko) * 1990-06-15 1999-08-02 루시에 라포인테-쇼우, 카르타 커티 케이 히루딘의 아미노산 시퀸스를 기재로 한 트롬빈 억제제

Also Published As

Publication number Publication date
SG79180A1 (en) 2001-03-20
US5433940A (en) 1995-07-18
HU211158A9 (en) 1995-10-30
JPH0768141B2 (ja) 1995-07-26
ATE137246T1 (de) 1996-05-15
DE122004000042I1 (de) 2005-02-24
HK1001562A1 (en) 1998-06-26
NO2004008I2 (no) 2008-01-28
DE122004000042I2 (de) 2008-01-24
NO920616D0 (no) 1992-02-17
NO310294B1 (no) 2001-06-18
FI102183B (fi) 1998-10-30
DE69026715T2 (de) 1996-10-17
NL300162I2 (nl) 2005-01-03
JPH04507253A (ja) 1992-12-17
US5691311A (en) 1997-11-25
HUT60285A (en) 1992-08-28
ES2086411T3 (es) 1996-07-01
KR100199534B1 (en) 1999-06-15
CA2065150A1 (en) 1991-02-19
CA2065150C (en) 1999-12-14
DK0489070T3 (da) 1996-07-15
LU91119I2 (fr) 2004-12-29
NO2004008I1 (no) 2004-12-27
NL300162I1 (nl) 2005-01-03
EP0489070A1 (en) 1992-06-10
EP0489070B1 (en) 1996-04-24
DE69026715D1 (en) 1996-05-30
FI920672A0 (fi) 1992-02-17
HU9200473D0 (en) 1992-05-28
WO1991002750A1 (en) 1991-03-07
US5196404B1 (en) 1996-09-10
NO920616L (no) 1992-04-13
AU6284190A (en) 1991-04-03
AU652125B2 (en) 1994-08-18
KR920702372A (ko) 1992-09-03
US5196404A (en) 1993-03-23

Similar Documents

Publication Publication Date Title
US5196404B1 (en) Inhibitors of thrombin
CA2079778A1 (en) Inhibitors of thrombin
PT816376E (pt) Inibidores de trombina como agentes anticoagulantes
ATE263157T1 (de) Nematizide trifluorbutene
PT912176E (pt) Utilizacao de amidas do acido piridil-alcanoico piridil-alcenoico e/ou piridil-alcinico para o tratamento de tumores ou para imunossupressao
BG102162A (en) Substituted (sulpphinic acid, sulphonic acid, sulphonylamino or sulphinylamino)n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylam ide compounds
SE8903773D0 (sv) Peraettiksyrakomposition
ATE121780T1 (de) Neue bacillus thuringiensis-stämme, verfahren zu ihrer isolierung und verwandte insektizidzusammensetzungen.
SE9604744D0 (sv) A modified coagulation agent
ATE130289T1 (de) 1,3-diphenyl-2-propin-1-one.
ATE7700T1 (de) 2-hydroxy-1,2,4-butantricarbonsaeure-oligoribosi - derivate, verfahren zu ihrer herstellung und ihre verwendung als prophylaktische mittel gegen zahnkaries.
ES2062513T3 (es) Metodo para purificar estreptoquinasas.

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20020001

Spc suppl protection certif: L20020002

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20040012

PC Transfer of assignment of patent

Owner name: HEALTH RESEARCH INCORPORATED

Free format text: HEALTH RESEARCH INCORPORATED

Owner name: BIOGEN IDEC MA INC.

Free format text: BIOGEN IDEC MA INC.

SPCG Supplementary protection certificate granted

Spc suppl protection certif: NUMBER:222